Targeted Treatment of Lymphoma, Leukaemia and Myeloma
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Methodology, Drug and Device Discovery".
Deadline for manuscript submissions: closed (20 July 2021) | Viewed by 56770
Special Issue Editor
Special Issue Information
Dear Collegues,
Our understanding of tumor biology has led to the development of several therapies targeting specific genes and proteins involved in the growth and survival of cancer cells. This transformation is most apparent in lymphoma, leukaemia and myeloma, where therapies targeting Bruton tyrosine kinase, phosphatidylinositol 3-kinase, B-cell lymphoma 2, the proteasome and the ubiquitin E3-ligase cereblon and are already in clinics.
The role of the immune system in tumor eradication has led to the development of second-generation CD20 antibodies, bi-specific antibodies and T-cell engagers, chimeric antigen receptor T-cells, and agents acting on key immune checkpoints such as programmed cell death protein 1 (PD1). Agents acting on DNA methylation or histone protein modification are also active in certain haemopoietic malignancies.
Several of these agents are superior to conventional chemoimmunotherapy although they are not without risk. Much of the current debate centers around sequencing of therapy, identification of rational combinations, the merits of fixed duration versus continuously administered therpay and long term toxicity. The answers to these questions likely to be determined when mature trial data is available.
This Special Issue will provide a comprehensive overview of current clinical research in lymphoma, leukaemia and myeloma with special reference to targeted therapies, including the utility of specific drugs/combinations and strategies in various clinical and biological subgroups.
Prof. Stephen Opat
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Lymphoma
- Chronic lymphocytic leukemia
- Acute lymphoblastic leukaemia
- Myeloma
- Bruton tyrosine kinase inhibitors
- BCL2 inhibitors/BH3 mimetics
- Phosphatidylinositol-3-kinase (PI-3 kinase) inhibitors
- Monoclonal antibodies
- Antibody-drug conjugates
- Bispecific antibodies/bispecific T cell engagers
- Selective inhibitors of nuclear export
- Chimeric antigen receptor T cells
- Hypomethylating agents
- Histone deacetylase inhibitors
- Histone methyltransferase inhibitors
- Immunomodulatory Agents
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.